Windtree Therapeutics, Inc. (NasdaqCM: WINT) recently showcased promising data on istaroxime, an investigational treatment ...

Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, today announced that ...

A cardiovascular specialty hospital in north Texas decreased time to diagnosis for patients with cardiogenic shock by more than half, according to a study published in Critical Care Nurse.

In this paper, we introduce a data processing pipeline for cardiogenic shock (CS) prediction from the MIMIC III database of intensive cardiac care unit patients with acute coronary syndrome. The ...

Cardiogenic shock (CS) is a life-threatening condition leading to poor prognosis and high morbidity. The related inadequate cardiac output carries to tissue hypoperfusion, hypoxia and multi-organ ...

Windtree Therapeutics (WINT) announced that Alexandre Mebazaa, MD, one of the world’s recognized leaders in cardiogenic shock, gave a ...

Most of the change in stage of cardiogenic shock (CS) occurred within the first 24 hours of presentation ... Mortality and use of temporary mechanical circulatory support was similar in stage E for ...

Baylor Scott & White The Heart Hospital-Plano in Texas cut times of cardiogenic shock diagnosis in half after implementing a quality improvement project that included nurse education and an ...

The FDA has opened up the use of Johnson & Johnson’s miniaturized heart pumps to certain pediatric patients, including those ...

The company has collaborated with ACTION to gather real-world data supporting the on-label use of heart pumps.

Physicians have a new treatment option for many of the sickest pediatric patients with heart failure and cardiogenic shock. Johnson & Johnson MedTech, the global leader in heart recovery, announced ...